Grant: CIHR Fellowship
McMaster University
$90,000.00
Characterization of the mechanisms of AmpC beta-lactamase mediated antibiotic resistance in Pseudomonas aerugionsa
EF 2012-13
Résumé
Pseudomonas aeruginosa is a prevalent environmental pathogen that is a leading cause of hospital-acquired infection in immunocompromised, burn, and cystic fibrosis patients. Treatment of P. aeruginosa is particularly challenging because of its resistance to nearly every antibiotic currently available. One of the primary mechanisms leading to resistance is the production of enzymes, called beta-lactamases, that degrade conventional antibiotics. Bacteria are surrounded by a mesh-like polymer, called peptidoglycan, that protects them from high internal pressures. Essential enzymes, called penicillin binding proteins (PBPs) and lytic transglycosylases (LTs), are responsible for maintaining and remodeling the peptidoglycan layer. Many conventional antibiotics, called beta-lactams, inhibit PBPs, thereby disrupting peptidoglycan maintenance and killing the bacterium. Interestingly, however, disruption of a specific PBP (PBP4) leads to an increase in beta-lactam antibiotic resistance by increasing the expression of beta-lactamase. In fact, many clinical strains of P. aeruginosa with high-level antibiotic resistance have mutations in the gene responsible for making PBP4. The mechanisms leading to this resistance are incompletely understood; however, they involve intricate coordination between two known regulatory pathways. Thus, we seek to understand how these pathways are linked, and to identify new molecules and therapies that can reverse antibiotic resistance in strains of P. aeruginosa with high levels of beta-lactamase. The findings of this study will shed light on future therapeutic targets in P. aeruginosa, and other similar Gram-negative bacteria. Additionally, this study will identify new drugs that block beta-lactamase production, thus preserving the efficacy of beta-lactams.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
281104
Name
Lamers Ryan P
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Characterization of the mechanisms of AmpC beta-lactamase mediated antibiotic resistance in Pseudomonas aerugionsa
Programtype2
Fellowship Programs
Orgnameinp2
McMaster University
Cihramount2
$90,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Ampc Beta-Lactamase; Anhydromuropeptides; Antibiotic Resistance; Beta-Lactam Resistance; Environmental Pathogens; Lytic Transglycosylases; Penicillin-Binding Proteins; Peptidoglycan Metabolism; Pseudomonas Aeruginosa; Two Component System
Abstract
Pseudomonas aeruginosa is a prevalent environmental pathogen that is a leading cause of hospital-acquired infection in immunocompromised, burn, and cystic fibrosis patients. Treatment of P. aeruginosa is particularly challenging because of its resistance to nearly every antibiotic currently available. One of the primary mechanisms leading to resistance is the production of enzymes, called beta-lactamases, that degrade conventional antibiotics. Bacteria are surrounded by a mesh-like polymer, called peptidoglycan, that protects them from high internal pressures. Essential enzymes, called penicillin binding proteins (PBPs) and lytic transglycosylases (LTs), are responsible for maintaining and remodeling the peptidoglycan layer. Many conventional antibiotics, called beta-lactams, inhibit PBPs, thereby disrupting peptidoglycan maintenance and killing the bacterium. Interestingly, however, disruption of a specific PBP (PBP4) leads to an increase in beta-lactam antibiotic resistance by increasing the expression of beta-lactamase. In fact, many clinical strains of P. aeruginosa with high-level antibiotic resistance have mutations in the gene responsible for making PBP4. The mechanisms leading to this resistance are incompletely understood; however, they involve intricate coordination between two known regulatory pathways. Thus, we seek to understand how these pathways are linked, and to identify new molecules and therapies that can reverse antibiotic resistance in strains of P. aeruginosa with high levels of beta-lactamase. The findings of this study will shed light on future therapeutic targets in P. aeruginosa, and other similar Gram-negative bacteria. Additionally, this study will identify new drugs that block beta-lactamase production, thus preserving the efficacy of beta-lactams.
Competitiondate
201302
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Lamers, Ryan P
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $90,000~ $0~